1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
2
|
Hao J and Chen WQ: The 10 most common
cancers in all registration areas. Chinese Cancer Registry Annual
Report (2012). Military Medical Science Press; Beijing, China: pp.
27–31. 2012
|
3
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Gramantieri L, Fornari F, Callegari E, et
al: MicroRNA involvement in hepatocellular carcinoma. J Cell Mol
Med. 12:2189–2204. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
6
|
Slaby O, Bienertova-Vasku J, Svoboda M and
Vyzula R: Genetic polymorphisms and microRNAs: new direction in
molecular epidemiology of solid cancer. J Cell Mol Med. 16:8–21.
2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Mishra PJ and Bertino JR: MicroRNA
polymorphisms: the future of pharmacogenomics, molecular
epidemiology and individualized medicine. Pharmacogenomics.
10:399–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Duan S, Mi S, Zhang W and Dolan ME:
Comprehensive analysis of the impact of SNPs and CNVs on human
microRNAs and their regulatory genes. RNA Biology. 6:412–425. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Xiao J, Lin H, Luo X, Luo X and Wang Z:
miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive
feedback loop in response to stress. EMBO J. 30:524–532. 2011.
View Article : Google Scholar
|
10
|
Jin L, Hu WL, Jiang CC, Wang JX, et al:
MicroRNA-149*, a p53-responsive microRNA, functions as
an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA.
108:15840–15845. 2011.PubMed/NCBI
|
11
|
Hong MJ, Choi YY, Jang JA, Jung HJ, et al:
Association between genetic variants in pre-microRNAs and survival
of early-stage NSCLC. J Thorac Oncol. 8:703–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhang MW, Jin MJ, Yu YX, et al:
Associations of lifestyle-related factors, hsa-miR-149 and
hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk.
Mol Carcinog. 51(Suppl 1): E21–E31. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Huang AJ, Yu KD, Li J, Fan L and Shao ZM:
Polymorphism rs4919510:C>G in mature sequence of human
microRNA-608 contributes to the risk of HER2-positive breast cancer
but not other subtypes. PLoS One. 7:e352522012.
|
14
|
Tu HF, Liu CJ, Chang CL, Wang PW, et al:
The association between genetic polymorphism and the processing
efficiency of miR-149 affects the prognosis of patients with head
and neck squamous cell carcinoma. PLoS One. 7:e516062012.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Xing J, Wan S, Zhou F, et al: Genetic
polymorphisms in pre-microRNA genes as prognostic markers of
colorectal cancer. Cancer Epidemiol Biomarkers Prev. 21:217–227.
2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kim WH, Min KT, Jeon YJ, et al:
Association study of microRNA polymorphisms with hepatocellular
carcinoma in Korean population. Gene. 504:92–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang J, Wang R, Ma YY, Chen LQ, Jin BH,
et al: Association between the single nucleotide polymorphisms in
miRNA196a-2 and miRNA146a and the susceptibility to hepatocellular
carcinoma in a Chinese population. Asian Pac J Cancer Prev.
14:6427–6431. 2013. View Article : Google Scholar
|
18
|
Lin RJ, Lin YC and Yu AL:
miR-149* induces apoptosis by inhibiting Akt1 and E2F1
in human cancer cells. Mol Carcinog. 49:719–727. 2010.
|
19
|
Ke Y, Zhao W, Xiong J and Cao R: miR-149
inhibits non-small-cell lung cancer cells EMT by targeting FOXM1.
Biochem Res Int. 2013:5067312013.PubMed/NCBI
|
20
|
Wang Y, Zheng X, Zhang Z, et al:
MicroRNA-149 inhibits proliferation and cell cycle progression
through the targeting of ZBTB2 in human gastric cancer. PLoS One.
7:e416932012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bashyam MD, Bair R, Kim YH, et al:
Array-based comparative genomic hybridization identifies localized
DNA amplifications and homozygous deletions in pancreatic cancer.
Neoplasia. 7:556–562. 2005. View Article : Google Scholar
|
22
|
Daido S, Takao S, Tamiya T, Ono Y, et al:
Loss of heterozygosity on chromosome 10q associated with malignancy
and prognosis in astrocytic tumors, and discovery of novel loss
regions. Oncol Rep. 12:789–795. 2004.PubMed/NCBI
|
23
|
Kim JH, Dhanasekaran SM, Mehra R, et al:
Integrative analysis of genomic aberrations associated with
prostate cancer progression. Cancer Res. 67:8229–8239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Ryan BM, McClary AC, Valeri N, Robinson D,
et al: rs4919510 in hsa-mir-608 is associated with outcome but not
risk of colorectal cancer. PLoS One. 7:e363062012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Landi D, Gemignani F, Barale R and Landi
S: A catalog of polymorphisms falling in microRNA-binding regions
of cancer genes. DNA Cell Biol. 27:35–43. 2008. View Article : Google Scholar : PubMed/NCBI
|